The risk of skin cancers in LFS patients was first detailed in a study of 71 unselected TP53 mutation carriers, which revealed a significantly greater cumulative risk of BCC and MM than did the general Dutch population, although SCC risk was not assessed due to the limited number of cases. This evidence concerns the gene TP53 and Miyoshi myopathy.